Pain Management Nursing
Volume 8, Issue 3, Supplement 1 , Pages S6-S13 , September 2007

New Opioid Formulations and Delivery Systems

  • Debra B. Gordon, RN, C, MS, APRN, FAAN

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Debra B. Gordon, RN, C, MS, APRN, FAAN, University of Wisconsin Hospital and Clinics, 600 Highland Avenue E5/616-6727, Madison, WI 53792.

References 

  1. Adams MP, Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs in R&D. 2005;6(2):91–99
  2. Adams M, Pieniaszek HJ, Gammaitoni AR, Ahdieh H. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. Journal of Clinical Pharmacology. 2005;45(3):337–345
  3. American Pain Society. (2003). Principles of analgesic use in the treatment of acute pain and cancer pain. Fifth ed. Glenview, IL.
  4. Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: A randomized 12-week clinical trial in osteoarthritis of the knee. Journal of Pain and Symptom Management. 2004;28(1):59–71
  5. Bovill, J. G. Recent advances in slow release drug formulations. Paper presented at: European Society of Anaesthesiology; May 28-31, 2005; Vienna, Austria.
  6. Carvalho B, Riley E, Cohen SE, Gambling D, Palmer C, Huffnagle HJ, et al. Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean delivery: Results of a multicenter randomized controlled study. Anesthesia and Analgesia. 2005;100(4):1150–1158
  7. Cephalon Inc. Fentora prescribing information. Retrieved November 22, 2006, from http://www.fentora.com/hcp/pi.pdf.
  8. Chan V, Valle-Leutri F, Clark J, Rossiter-Rooney M. Self-titrated aerosolized liposome-encapsulated fentanyl rests in rapid onset and sustained analgesia following ACL knee surgery. Anesthesiology. 2004;101:A77
  9. Chelly JE. An iontophoretic, fentanyl HCl patient-controlled transdermal system for acute postoperative pain management. Expert Opinion on Pharmacotherapy. 2005;6(7):1205–1214
  10. Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: A multicenter, placebo-controlled trial. Anesthesia and Analgesia. 2004;98(2):427–433table of contents
  11. Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Current Medical Research and Opinion. 2004;20(9):1419–1428
  12. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Pharmacokinetic properties of fentanyl effervescent buccal tablets: A phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical Therapeutics. 2006;28(5):707–714
  13. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain. 1996;64(3):527–534
  14. Durect Corporation. Chronogesic pain therapy system. Retrieved November 10, 2006, from http://www.durect.com/wt/durect/page_name/chronogesic.
  15. Durect Corporation. Remoxy. Retrieved November 22, 2006, from http://www.durect.com/wt/durect/page_name/remoxy.
  16. Elite Pharmaceuticals Inc. Elite holds clinical guidance meeting with the FDA on its abuse deterrent pain program. Retrieved November 22, 2006, from http://www.elitepharma.com/investor_relations.asp?goto=275.
  17. Endo Pharmaceuticals Inc. Opana IR prescribing information. http://www.opana.com/pdfs/opana_er_pi.pdf. Accessed November 21, 2006.
  18. Fisher DM, Kellett N, Lenhardt R. Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. Anesthesiology. 2003;99(4):929–937
  19. Gallagher RE, Arndt DR, Hunt KL. Analgesic effects of topical methadone: a report of four cases. Clinical Journal of Pain. 2005;21(2):190–192
  20. Gordon DB. Oral transmucosal fentanyl citrate for cancer breakthrough pain: A review. Oncology Nursing Forum. 2006;33(2):257–264
  21. Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. Journal of Pain. 2006;8(2):175–184
  22. Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. Journal of Pain. 2005;6(1):21–28
  23. IONSYS prescribing information. Retrieved November 22, 2006, from http://www.ionsys.net/active/janus/en_US/assets/common/company/pi/ionsys.pdf#zoom=100.
  24. Janssen Pharmaceutica Products LP. Duragesic full prescribing information. Retrieved November 22, 2006, from http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf#zoom=100.
  25. Kadian full prescribing information. Retrieved November 21, 2006, from http://www.kadian.com/pages/getfile.aspx?id=1C6197AB-8F83-43E7-B239-D4615293989B.
  26. Ligand Pharmaceuticals Inc. Avinza product information. Retrieved November 21, 2006, from http://www.ligand.com/pdf/AVINZAPI.pdf
  27. Medical News Today. Alpharma Data Demonstrates Alcohol Does Not Significantly Affect Pharmacokinetics Of KADIAN(R) Capsule. Retrieved April 27, 2007, from http://www.medicalnewstoday.com/medicalnews.php?newsid=62730.
  28. Medical News Today. Cephalon’s fentanyl effervescent buccal tablet reduces intensity of breakthrough pain in cancer patients. Retrieved November 9, 2006, from http://www.medicalnewstoday.com/medicalnews.php?newsid=42814.
  29. McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study. American Journal of Therapeutics. 2005;12(2):106–112
  30. Otis J, Rothman M. A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Current Medical Research and Opinion. 2006;22(8):1493–1501
  31. Pain and Policies Study Group. Achieving balance in federal and state pain policy: A guide to evaluation. 3rd. Retrieved November 6, 2006, from http://www.painpolicy.wisc.edu/Achieving_Balance/EG2006.pdf.
  32. Pain Therapeutics Inc. Remoxy. Retrieved November 22, 2006, from http://www.paintrials.com/remoxy.html.
  33. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. Journal of Clinical Oncology. 1998;16(4):1588–1593
  34. Phosphagenics Limited. Favourable toxicology results support broadening transdermal morphine (TPM-01/Morphine) clinical program. Retrieved November 6, 2006, from http://www.phosphagenics.com/documents/news/10%20Oct%202006%20-%20TPM01%20Morphine%20Toxicology%20Update.pdf.
  35. Phosphagenics Limited. Transdermal Morphine. Retrieved November 6, 2006, from http://vitalcapital.com/main/pharms_morphine.htm.
  36. Rogers JF, Nafziger AN, Bertino JS. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. The American Journal of Medicine. 2002;113(9):746–750
  37. Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer. 2005;13(1):57–65Epub 2004 Nov 2009
  38. Staniforth JN, Baichwal AR. TIMERx: Novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opinion on Drug Delivery. 2005;2(3):587–595
  39. Stoker, D., Reber, K., Carr, D. B., Ernst, C., Gawarecki, D., Hamilton, D. et al. Rylomine (intranasal morphine), a non-invasive alternative to injectable morphine: Characterization of analgesic properties and side effects in moderate-to-severe postsurgical pain. Paper presented at: 22nd Annual Meeting of the American Academy of Pain Medicine, 2006; San Diego, California.
  40. Striebel HW, Oelmann T, Spies C, Rieger A, Schwagmeier R. Patient-controlled intranasal analgesia: A method for noninvasive postoperative pain management. Anesthesia and Analgesia. 1996;83(3):548–551
  41. Taylor, D., Portenoy, R. K., Messina, J., & Tremmel, L. A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer: Poster 729. Paper presented at: 25th Annual Scientific Meeting of the American Pain Society, 2006; San Antonio, Texas.
  42. Tramadol-Biovail Corporation. Drugs in R&D. 2004;5(3):182–183
  43. Twillman RK, Long TD, Cathers TA, Mueller DW. Treatment of painful skin ulcers with topical opioids. Journal of Pain and Symptom Management. 1999;17(4):288–292
  44. Ultram ER prescribing information. Retrieved November 22, 2006, from http://www.ortho-mcneil.com/active/janus/en_US/assets/common/company/pi/ultramer.pdf; jsessionid=XWEZYD4RXSCPUCQPCCEDC0YKB2IIWNSC.
  45. Viscusi ER, Martin G, Hartrick CT, Singla N, Manvelian G. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology. 2005;102(5):1014–1022
  46. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. The Journal of the American Medical Association. 2004;291(11):1333–1341

PII: S1524-9042(07)00047-1

doi: 10.1016/j.pmn.2007.04.002

Pain Management Nursing
Volume 8, Issue 3, Supplement 1 , Pages S6-S13 , September 2007

Article Tools